about
Assessing the Methodology for Calculating Platelet Contribution to Clot Strength (Platelet Component) in Thromboelastometry and ThrombelastographyPostoperative hypoxia and length of intensive care unit stay after cardiac surgery: the underweight paradox?Hypothermic cardiopulmonary bypass as a determinant of late thrombocytopenia following cardiac operations in pediatric patients.Hemostatic and thrombotic issues in cardiac surgery.Can the Viscoelastic Parameter α-Angle Distinguish Fibrinogen from Platelet Deficiency and Guide Fibrinogen Supplementation?International cooperation in healthcare: model of IRCCS Policlinico San Donato and Bambini Cardiopatici nel Mondo Association for congenital heart diseases.The care for adults with congenital heart disease: organization and function of a grown-up congenital heart disease unit.Transcatheter aortic valve replacement-state of the art and a glimpse to the future: 'the Tailored Approach'Intensive care unit admission parameters improve the accuracy of operative mortality predictive models in cardiac surgeryCentral venous oxygen saturation and blood lactate levels during cardiopulmonary bypass are associated with outcome after pediatric cardiac surgery.Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patientsComparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox ®) versus thromboelastometry (ROTEM ®).Hemodilution on cardiopulmonary bypass as a determinant of early postoperative hyperlactatemia.Hyperlactatemia during cardiopulmonary bypass: determinants and impact on postoperative outcomeO2 delivery and CO2 production during cardiopulmonary bypass as determinants of acute kidney injury: time for a goal-directed perfusion management?Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenationRandomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery.Baroreflex sensitivity and outcomes following coronary surgery.In search of the ideal risk-scoring system for very high-risk cardiac surgical patients: a two-stage approachEffect of haematocrit on fibrin-based clot firmness in the FIBTEM test.Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials.Management of mini-cardiopulmonary bypass devices: is it worth the energy?Universal definition of perioperative bleeding in adult cardiac surgery.Albumin-Beyond Fluid Replacement in Cardiopulmonary Bypass Surgery: Why, How, and When?Perioperative management of patients receiving new oral anticoagulants: an international survey.Pre-operative fibrinogen supplementation in cardiac surgery patients: an evaluation of different trigger values.Outcome measures and quality markers for perioperative blood loss and transfusion in cardiac surgery.Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS).Modern ECMO: why an ECMO programme in a tertiary care hospital.Preoperative colonization in pediatric cardiac surgery and its impact on postoperative infections.Transcatheter aortic valve replacement in nonagenarians: early and intermediate outcome from the OBSERVANT study and meta-analysis of the literature.Carbon dioxide production during cardiopulmonary bypass: pathophysiology, measure and clinical relevance.Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages 3b to 5.Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both?Fibrinogen Levels After Cardiac Surgical Procedures: Association With Postoperative Bleeding, Trigger Values, and Target Values.Early and Midterm Outcome of Propensity-Matched Intermediate-Risk Patients Aged ≥80 Years With Aortic Stenosis Undergoing Surgical or Transcatheter Aortic Valve Replacement (from the Italian Multicenter OBSERVANT Study).Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST).Rhinocerebral zygomycosis: an unusual dramatic presentation in a paediatric cardiac patient without risk factors.Immediate and Intermediate Outcome After Transapical Versus Transfemoral Transcatheter Aortic Valve Replacement.Outcome After General Anesthesia Versus Monitored Anesthesia Care in Transfemoral Transcatheter Aortic Valve Replacement.
P50
Q26785877-03419CC6-0A7A-440D-999F-4E504129FEFEQ31157877-EC441E02-8D98-46C2-9CEF-57C59060527FQ33384838-36F450F2-326A-4F78-B507-A62068B2C9EEQ33419784-10EEA229-3341-4BBB-8605-62D3C36EBAC6Q33424644-9A5805F0-5799-4158-B3EE-1DE706560C23Q33646843-01E3B9BF-D0A6-4646-BDAE-A2E0D49C7121Q33646848-E31D887E-9E6B-4417-80EA-13349F32B5B7Q33646856-52736FB9-C259-485D-A5E1-FDFAC1416394Q33735818-44EC4E32-4D66-4ADA-831E-FF51E306CCF9Q34153341-CBAE54BA-F9F9-406C-8342-899D749F53B6Q34233833-23DE168E-D547-45FD-8FD0-714351B28399Q35318068-025182B6-A41C-494E-8A56-BF7798D575BDQ35620682-A8233070-1D3E-470B-A7E9-47B35F4513A1Q35629906-701FB3B1-50B2-40C1-9C6D-A3055A42D4EEQ36070501-403CB296-9769-494B-BBF6-376C1103EBC8Q36073211-B3EFEDB9-B744-4DDA-8A11-78055298CF51Q36142046-4D856857-79C9-44E7-8ABD-9CE90FF25E62Q36338006-D8D38784-F3C4-457E-8DD9-061D2D037932Q36476317-2BF34FA0-C012-47ED-81CD-F6F5B3C23786Q37059236-376CB5F5-3DE5-4BFF-95FC-A2675B7FAAE5Q37112389-E1B8FFFA-28EB-497C-AD62-79DB3E9B59B5Q37399841-3B627DD8-CEE9-4296-BF97-2C0C5C5054BCQ38170733-B0BDD2B8-1D14-407A-B811-49B402CD1D1BQ38214993-1E37CAD6-9E25-4F6A-BAAB-247F3548CB7DQ38244376-0B70CB2E-4800-472E-82FB-E95801FE760FQ38323863-61D42F18-5765-47D8-A6C1-5F987C2FDED0Q38614138-797E56C6-8501-4DB6-88AC-24273ECCE51BQ38714585-B122F688-550C-4D60-BAF3-B49F8A68C9F2Q38769833-0CCA1467-93EB-4B18-91FB-F135BC3B993FQ38786244-0C969550-1639-46EE-B06D-7E612A171EC3Q38850807-32BD507F-BF4A-4C2E-B1A9-1482AF315833Q38902517-B135AA93-0DA6-482E-97C6-56D230AF1A46Q39808527-38A6E497-F4F9-4CC8-B5A8-763743F605E7Q39859238-4CDFF527-556B-4A40-A31A-5A8EB683DED0Q39884102-633E9AF5-AD1F-4375-A40C-310942B26BEFQ39906543-F15BBE6B-8643-4C7F-95AC-E03BA1A7CA4AQ39985273-54F9AB85-A70F-4DC0-A069-9C19321A2291Q40202688-3BE7999E-A3EC-4167-AA92-4819E4BDD37FQ40240747-AA63BF92-CE44-4164-9CFD-9BED211AB382Q40633774-F11C36D3-D20F-4B05-9FE4-798B1BA36E8A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Ranucci
@ast
Marco Ranucci
@en
Marco Ranucci
@es
Marco Ranucci
@nl
Marco Ranucci
@sl
type
label
Marco Ranucci
@ast
Marco Ranucci
@en
Marco Ranucci
@es
Marco Ranucci
@nl
Marco Ranucci
@sl
prefLabel
Marco Ranucci
@ast
Marco Ranucci
@en
Marco Ranucci
@es
Marco Ranucci
@nl
Marco Ranucci
@sl
P1053
K-1040-2016
P106
P1153
57190090742
7003733509
P21
P31
P3829
P496
0000-0002-4915-3572